# Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

> **NCT02521493** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Children's Oncology Group** · enrollment: 280 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Down Syndrome
- Myelodysplastic Syndrome
- Myeloid Leukemia Associated With Down Syndrome
- Myeloproliferative Neoplasm

## Interventions

- **DRUG:** Asparaginase
- **DRUG:** Asparaginase Erwinia chrysanthemi
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin Hydrochloride
- **DRUG:** Etoposide
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Mitoxantrone Hydrochloride
- **DRUG:** Thioguanine

## Key facts

- **NCT ID:** NCT02521493
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-12-23
- **Primary completion:** 2024-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 280 (ACTUAL)
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02521493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02521493, "Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02521493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*